-

Agilent Announces Bravo NGS Automated Liquid Handling Platform with On-Deck Thermal Cycler

Enhanced user experience in NGS sample preparation workflow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of an on-deck thermal cycler (ODTC) that integrates with the Agilent Bravo NGS automated liquid handling platform. The optional ODTC accessory enables the Bravo platform to provide thermal cycling as part of an automated workflow for next-generation sequencing (NGS), end-point PCR, and cell-based applications.

An on-deck thermal cycler is critical in many genomics and molecular biology workflows. This optional accessory enables the Bravo NGS automated liquid handling platform to provide thermal cycling as part of an automated protocol and increases "walk-away" time, providing operators with more freedom to focus on higher-level tasks. This setup is beneficial, particularly for applications such as library preparation and target enrichment steps in NGS workflows.

"The on-deck thermal cycler enables more seamless workflows on Bravo NGS platforms by eliminating multiple touch points where users must remove a microplate from the Bravo deck and place it on an offline, third-party thermal cycling instrument," said Lars Kristiansen, general manager of Agilent’s Automation Solutions Business. "Adding an ODTC to the Bravo platform extends walk-away opportunities, improves performance, and enhances ease-of-use with preprogrammed protocols. This release supports our customers in high-throughput academic and service provider labs who want to improve productivity and reproducibility while maintaining workflow flexibility."

Kevin Kim, head of automation at Avellino Labs, added, "The Bravo with ODTC is a cost-effective and powerful addition to any lab that needs a solution with more walk-away time, smaller footprint, and direct pipetting into the thermal cycler, which is critical for temperature-sensitive assay steps."

Kevin Meldrum, general manager of Agilent’s Integrated Genomics Division, added, “With the ODTC on the Bravo, SureSelect users will have an enhanced experience while taking advantage of the flexibility and quality performance of the SureSelect XT HS2 chemistry.”

Agilent’s modular workflow solutions are designed to integrate easily and work together seamlessly. The Agilent Bravo NGS workstation with ODTC integrates with SureSelect reagents to provide an automated NGS solution that saves time and minimizes the burden of optimizing new automated assays while providing the flexibility to serve a broad range of application needs.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so...

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in sit...

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...
Back to Newsroom